VCYT logo

VERACYTE INC

VCYTNASDAQ
🏆 #1555 by market capUS Equity
$46.09▲ $0.87 (+1.88%)
After hours · at close
🔔
Track VCYT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.9%
7d▲ 6.3%
14d▲ 14.8%
30d▲ 6.3%
ytd▲ 9.4%
1y▲ 37.0%
🏦Market Cap
$3.68B
Small Cap
📈Revenue Growth (YoY)
+16.0%
Healthy
📊Gross Margin
72.1%
High
💵FCF Margin
29.4%
Strong
⚖️P/S Ratio
6.5x
Fair
Otter Score
72
Fair

Trading Snapshot

Day Range
$45.92 – $46.78
52-Week Range
$29.46 – $60.91
Volume
$4.48B
Avg Volume
$5.15B
Shares Outstanding
79.8M
Next Earnings
Nov 17, 2026

Fundamentals Snapshot

Annual Revenue
$517M
Last Q Revenue
$150M
P/E Ratio
32.0
P/S Ratio
6.5x
EPS (TTM)
$1.44
Dividend Yield
0.00%
Dilution (1yr)
+1.9%

Why Investors Own VCYT

  • ✓High-growth profile — revenue up +51.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 68% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

VCYT logo

VERACYTE INC

VCYT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$517M▲ +16.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
69.6%▲ +4.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$74M▲ +359.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$127M▲ +98.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
81.4M▲ +1.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$323M▲ +$135M YoY
StockOtter · stockotter.space

About VERACYTE INC

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$59.00
▲ +28.0% Upside
High Target$71.97
Low Target$44.74
Based on 10 analysts

Latest News & Updates

🚀
Reuters·2h ago

VERACYTE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift VCYT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

VERACYTE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.